Biobanking Market by Product, Sample Type, Storage Type, Application, End-User

List of Tables

The Biobanking Market was valued at USD 70.33 billion in 2023, expected to reach USD 78.21 billion in 2024, and is projected to grow at a CAGR of 11.71%, to USD 152.75 billion by 2030.

Biobanking refers to the collection, processing, storage, and management of biological samples for research and clinical care, playing an essential role in advancing personalized medicine, genomics, and drug development. The necessity of biobanking arises from the growing need for high-quality biomaterials to support biomedical research, enabling breakthroughs in disease understanding and therapeutic innovation. Its applications span across various domains, including cancer research, genetic disorder studies, and epidemiology. End-users range from academic and research institutions to pharmaceutical companies and hospitals. Key growth factors influencing the biobanking market include the surge in chronic disease prevalence, advancements in regenerative medicine, and increased funding for R&D activities. The expanding adoption of precision medicine further amplifies its importance. However, biobanking faces limitations such as stringent regulatory requirements, ethical concerns regarding privacy and consent, and challenges in sample storage and preservation technologies. Moreover, limited data access and interoperability between biobanks can impede progress. Emerging opportunities in the market include the integration of artificial intelligence and big data analytics to enhance data management and interpretation. Additionally, the development of mobile and decentralized biobanking approaches can broaden sample diversity and representation. Innovative areas for business growth include the creation of standardized protocols for sample handling and blockchain applications for secure data sharing. Improving community engagement and fostering public trust remain critical to overcoming ethical challenges and boosting participation in biobanking initiatives. The nature of the biobanking market is competitive yet collaborative, with opportunities for partnerships among biotechnology firms, academic institutions, and healthcare providers. Companies venturing into this space should focus on enhancing their technological infrastructure and forming strategic alliances to harness emerging technologies effectively. Overall, biobanking stands at the forefront of transformative healthcare solutions, with research and innovation being pivotal to unlocking its potential.

KEY MARKET STATISTICS
Base Year [2023]	USD 70.33 billion
Estimated Year [2024]	USD 78.21 billion
Forecast Year [2030]	USD 152.75 billion
CAGR (%)	11.71%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Biobanking Market

The Biobanking Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

Market Drivers
- Increasing burden of chronic diseases across economies and need for better healthcare infrastructure
- Growing private and public investments in pharmaceutical research
- Rising awareness and government initiatives in regenerative medicine
Market Restraints
- Problems associated with procedure harmonization due to decentralized nature of biobanks
Market Opportunities
- Ongoing research to improve and ensure standardization of data acquisition and analysis in biobanks
- Emerging focus on biobank sustainability and development of imaging biobanks
Market Challenges
- Ethical and legal concerns associated with biobanking

Porter's Five Forces: A Strategic Tool for Navigating the Biobanking Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Biobanking Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Biobanking Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Biobanking Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Biobanking Market

A detailed market share analysis in the Biobanking Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Biobanking Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Biobanking Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Biobanking Market

A strategic analysis of the Biobanking Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Biobanking Market, highlighting leading vendors and their innovative profiles. These include AMS Biotechnology (Europe) Limited, ASKION GmbH, Avantor, Inc., Azenta Life Sciences, Bay Biosciences LLC, Becton, Dickinson and Company, BioIVT LLC, BioKryo by L'AIR LIQUIDE S.A., BocaBio, Charles River Laboratories International, Inc., Cryoport Systems, LLC, CTIBiotech, Cureline, Inc., Firalis Group, Greiner AG, Hamilton Company, Merck KgaA, Micronic Holding B.V., PHC Holdings Corporation, Promega Corporation, ProteoGenex, QIAGEN N.V., Sopachem NV/SA, SPT Labtech Ltd., STEMCELL Technologies Inc., Taylor-Wharton, Tecan Trading AG, Thermo Fisher Scientific Inc., UK Biobank Limited, and US Biolab Corporation, Inc..

Market Segmentation & Coverage

This research report categorizes the Biobanking Market to forecast the revenues and analyze trends in each of the following sub-markets:

Based on Product, market is studied across Consumables, Equipment & Instruments, Services, and Software.
Based on Sample Type, market is studied across Biological Fluids, Blood Products, Cell Lines, Human Tissues, and Nucleic Acids.
Based on Storage Type, market is studied across Automated and Manual.
Based on Application, market is studied across Clinical Research, Life Science Research, and Regenerative Medicine.
Based on End-User, market is studied across Academic & Research Institutes, Hospitals, and Pharmaceutical & Biotechnology.
Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Product Code: MRR-961BA04A2DC3

1. Preface

1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders

2. Research Methodology

2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

5.1. Market Dynamics
- 5.1.1. Drivers
  - 5.1.1.1. Increasing burden of chronic diseases across economies and need for better healthcare infrastructure
  - 5.1.1.2. Growing private and public investments in pharmaceutical research
  - 5.1.1.3. Rising awareness and government initiatives in regenerative medicine
- 5.1.2. Restraints
  - 5.1.2.1. Problems associated with procedure harmonization due to decentralized nature of biobanks
- 5.1.3. Opportunities
  - 5.1.3.1. Ongoing research to improve and ensure standardization of data acquisition and analysis in biobanks
  - 5.1.3.2. Emerging focus on biobank sustainability and development of imaging biobanks
- 5.1.4. Challenges
  - 5.1.4.1. Ethical and legal concerns associated with biobanking
5.2. Market Segmentation Analysis
- 5.2.1. Product: Expanding software integration to facilitate the biobanking operations
- 5.2.2. Sample Type: Increasing use of nucleic acid sample for genetic study
- 5.2.3. Storage Type: Rising preference for automated storage systems due to its efficiency and scalability
- 5.2.4. End-User: Expansion of biobanks in pharmaceutical sector for drug development
5.3. Porter's Five Forces Analysis
- 5.3.1. Threat of New Entrants
- 5.3.2. Threat of Substitutes
- 5.3.3. Bargaining Power of Customers
- 5.3.4. Bargaining Power of Suppliers
- 5.3.5. Industry Rivalry
5.4. PESTLE Analysis
- 5.4.1. Political
- 5.4.2. Economic
- 5.4.3. Social
- 5.4.4. Technological
- 5.4.5. Legal
- 5.4.6. Environmental

6. Biobanking Market, by Product

6.1. Introduction
6.2. Consumables
6.3. Equipment & Instruments
6.4. Services
6.5. Software

7. Biobanking Market, by Sample Type

7.1. Introduction
7.2. Biological Fluids
7.3. Blood Products
7.4. Cell Lines
7.5. Human Tissues
7.6. Nucleic Acids

8. Biobanking Market, by Storage Type

8.1. Introduction
8.2. Automated
8.3. Manual

9. Biobanking Market, by Application

9.1. Introduction
9.2. Clinical Research
9.3. Life Science Research
9.4. Regenerative Medicine

10. Biobanking Market, by End-User

10.1. Introduction
10.2. Academic & Research Institutes
10.3. Hospitals
10.4. Pharmaceutical & Biotechnology

11. Americas Biobanking Market

11.1. Introduction
11.2. Argentina
11.3. Brazil
11.4. Canada
11.5. Mexico
11.6. United States

12. Asia-Pacific Biobanking Market

12.1. Introduction
12.2. Australia
12.3. China
12.4. India
12.5. Indonesia
12.6. Japan
12.7. Malaysia
12.8. Philippines
12.9. Singapore
12.10. South Korea
12.11. Taiwan
12.12. Thailand
12.13. Vietnam

13. Europe, Middle East & Africa Biobanking Market

13.1. Introduction
13.2. Denmark
13.3. Egypt
13.4. Finland
13.5. France
13.6. Germany
13.7. Israel
13.8. Italy
13.9. Netherlands
13.10. Nigeria
13.11. Norway
13.12. Poland
13.13. Qatar
13.14. Russia
13.15. Saudi Arabia
13.16. South Africa
13.17. Spain
13.18. Sweden
13.19. Switzerland
13.20. Turkey
13.21. United Arab Emirates
13.22. United Kingdom

14. Competitive Landscape

14.1. Market Share Analysis, 2023
14.2. FPNV Positioning Matrix, 2023
14.3. Competitive Scenario Analysis
- 14.3.1. New biobanking partnership safeguards the genetic diversity of America's endangered species
- 14.3.2. Crown Bioscience to Acquire Indivumed's Service Business and Supporting Biobank
- 14.3.3. CNIO biobank receives EUR 800,000 from the EU
14.4. Strategy Analysis & Recommendation

Companies Mentioned

1. AMS Biotechnology (Europe) Limited
2. ASKION GmbH
3. Avantor, Inc.
4. Azenta Life Sciences
5. Bay Biosciences LLC
6. Becton, Dickinson and Company
7. BioIVT LLC
8. BioKryo by L'AIR LIQUIDE S.A.
9. BocaBio
10. Charles River Laboratories International, Inc.
11. Cryoport Systems, LLC
12. CTIBiotech
13. Cureline, Inc.
14. Firalis Group
15. Greiner AG
16. Hamilton Company
17. Merck KgaA
18. Micronic Holding B.V.
19. PHC Holdings Corporation
20. Promega Corporation
21. ProteoGenex
22. QIAGEN N.V.
23. Sopachem NV/SA
24. SPT Labtech Ltd.
25. STEMCELL Technologies Inc.
26. Taylor-Wharton
27. Tecan Trading AG
28. Thermo Fisher Scientific Inc.
29. UK Biobank Limited
30. US Biolab Corporation, Inc.